EDAP TMS Announces Reimbursement Approval In Switzerland For The Use Of High-Intensity Focused Ultrasound In The Treatment Of Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
EDAP TMS has received approval for reimbursement in Switzerland for the use of its High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This approval could potentially increase the adoption of EDAP's HIFU technology in Switzerland.
July 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EDAP TMS has received reimbursement approval in Switzerland for its HIFU technology. This could potentially increase the adoption of the technology in Switzerland, positively impacting EDAP's revenues.
Reimbursement approval is a significant milestone for medical technology companies as it can lead to increased adoption of their technology. In this case, the approval in Switzerland could potentially increase the adoption of EDAP's HIFU technology in the country, leading to increased revenues for the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100